Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) for the inspection conducted by the US Food and Drug Administration (USFDA) at its API-I and API-II facilities in Panelav.

The inspection was carried out between May 26, 2025 and May 31, 2025.

Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5,500 are well recognized by doctors and patients.